Expert opinion on drug metabolism & toxicology最新文献_第4页

Drug-drug interactions in metastatic hormone-sensitive prostate cancer (mHSPC): practical considerations for treating men with androgen receptor pathway inhibitors and common medications in this stage. 转移性荷尔蒙敏感性前列腺癌（mHSPC）的药物相互作用：使用雄激素受体通路抑制剂和此阶段常用药物治疗男性的实际注意事项。

Expert opinion on drug metabolism & toxicology Pub Date : 2025-06-01 Epub Date: 2025-03-19 DOI: 10.1080/17425255.2025.2478167

Cristina Ibáñez, Manuel Tourís-Lores, Álvaro Montesa, Fernando López-Campos, Emilio Ríos, Paola Usán, Cristina Moretones, David Conde-Estévez

{"title":"Drug-drug interactions in metastatic hormone-sensitive prostate cancer (mHSPC): practical considerations for treating men with androgen receptor pathway inhibitors and common medications in this stage.","authors":"Cristina Ibáñez, Manuel Tourís-Lores, Álvaro Montesa, Fernando López-Campos, Emilio Ríos, Paola Usán, Cristina Moretones, David Conde-Estévez","doi":"10.1080/17425255.2025.2478167","DOIUrl":"10.1080/17425255.2025.2478167","url":null,"abstract":"Introduction: New androgen receptor pathway inhibitors (ARPIs) are an essential part of the treatment strategy for patients with metastatic hormone-sensitive prostate cancer (mHSPC). Despite the good tolerability of ARPIs, after treatment is started, drug-drug interactions (DDIs) between these and other medications frequently taken by these patients may appear. DDIs may reduce the therapeutic effect of both and lead to increased adverse events. DDIs should be carefully assessed before an ARPI is started.Areas covered: We first review the current therapeutic landscape for mHSPC, common age-related comorbidities and other comorbidities or adverse events arising from previous or current treatments for prostate cancer, and patients' symptomatology. We then analyze the potential toxicities arising from medications for these conditions and those of mHSPC: ARPIs (abiraterone acetate plus prednisone/prednisolone, enzalutamide, apalutamide, and darolutamide) and docetaxel.Expert opinion: Before mHSPC patients are treated with an ARPI, careful assessment of patient eligibility for each treatment alternative and potential DDIs between these and treatments for current comorbidities is a fundamental component in clinical decision-making. ARPIs with low potential DDIs allow keeping current concomitant medications without significant relevant dose adjustments and help reduce the risk of toxicities and comorbidity-related decompensation.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"625-636"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143631100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinically significant drug-drug interactions involving opioid analgesics used for pain treatment in patients with cancer: update of a systematic review. 用于癌症患者疼痛治疗的阿片类镇痛药的临床显著药物-药物相互作用：一项系统综述的更新。

Expert opinion on drug metabolism & toxicology Pub Date : 2025-06-01 Epub Date: 2025-04-28 DOI: 10.1080/17425255.2025.2491743

Aleksandra Kotlińska-Lemieszek, Pål Klepstad, Dagny Faksvåg Haugen

{"title":"Clinically significant drug-drug interactions involving opioid analgesics used for pain treatment in patients with cancer: update of a systematic review.","authors":"Aleksandra Kotlińska-Lemieszek, Pål Klepstad, Dagny Faksvåg Haugen","doi":"10.1080/17425255.2025.2491743","DOIUrl":"10.1080/17425255.2025.2491743","url":null,"abstract":"Introduction: Drug-drug interactions (DDIs) are among factors that may affect the efficacy and safety of opioid treatment. Data on clinically manifested DDIs are scarse, and recommendations that might guide physicians are presently lacking. The aim of this study was to update a systematic review (2015) on studies reporting clinically significant DDIs involving opioids used for pain treatment in adult patients with cancer.Methods: Systematic literature searches in MEDLINE, Embase, and Cochrane Central Register of Controlled Trials from the start of the databases through 18 September 2023.Results: Of the 1968 retrieved papers, 16 were included in the final analysis, together with five papers identified through hand-searching of reference lists. Nineteen publications were case reports or case series. Nine, sixteen, and eight patients presented adverse effects from opioids, impaired pain control, or opioid withdrawal, respectively. The main mechanisms underlying DDIs were alteration of cytochrome P450 3A4 activity and pharmacodynamic antagonism resulting from concurrent use of an opioid analgesic and a peripheral mu-opioid receptor antagonist (PAMORA).Conclusion: Knowledge about clinically significant DDIs associated with opioids in cancer patients is currently mostly based upon case reports. These cases give information about drug combinations that should be recognized as potentially harmful by physicians prescribing opioids.Prospero id: CRD42023481103.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"703-715"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144061390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ceftobiprole medocaril for skin and skin-structure infections. 头孢双prole medocaril用于皮肤和皮肤结构感染。

Expert opinion on drug metabolism & toxicology Pub Date : 2025-05-01 Epub Date: 2025-03-06 DOI: 10.1080/17425255.2025.2474127

Matthew W McCarthy

{"title":"Ceftobiprole medocaril for skin and skin-structure infections.","authors":"Matthew W McCarthy","doi":"10.1080/17425255.2025.2474127","DOIUrl":"10.1080/17425255.2025.2474127","url":null,"abstract":"Introduction: On 3 April 2024, the United States Food and Drug Administration (FDA) approved ceftobiprole medocaril sodium (Zevtera) for injection for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI) as well as patients with Staphylococcus aureus bloodstream infections and patients 3 months to less than 18 years old with community-acquired bacterial pneumonia.Areas covered: Ceftobiprole is a fifth-generation cephalosporin that exerts antibacterial activity by binding to penicillin-binding proteins and inhibiting transpeptidases and has demonstrated broad antimicrobial activity against both Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). This manuscript involves a literature review of PubMed from 1 February 2024 through 8 January 2025.Expert opinion: Ceftobiprole has demonstrated clinical efficacy in treating ABSSSI in a randomized, controlled, double-blind, multinational trial. The pharmacokinetics of this drug, coupled with its favorable safety profile, suggest ceftobiprole will be an important addition to the antimicrobial armamentarium. In the future, ceftobiprole may be used alone or in combination to treat antibiotic-resistant infections, which serve as an expanding threat to patients with and without immune impairment.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"519-523"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143545299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating the pharmacokinetics of zolbetuximab in gastric adenocarcinoma. 唑贝昔单抗在胃腺癌中的药动学评价。

Expert opinion on drug metabolism & toxicology Pub Date : 2025-05-01 Epub Date: 2025-03-04 DOI: 10.1080/17425255.2025.2474122

Jane E Rogers, Michael Leung, Jaffer A Ajani

{"title":"Evaluating the pharmacokinetics of zolbetuximab in gastric adenocarcinoma.","authors":"Jane E Rogers, Michael Leung, Jaffer A Ajani","doi":"10.1080/17425255.2025.2474122","DOIUrl":"10.1080/17425255.2025.2474122","url":null,"abstract":"Introduction: Gastric adenocarcinoma (GAC) represents a heterogeneous disease making treatment advancements difficult. Recently, claudin 18.2 (CLDN18.2) has emerged as an exciting new target in GAC. Zolbetuximab, an anti-CLDN18.2 monoclonal antibody, has now been FDA approved.Areas covered: Phase 1, 2, and 3 zolbetuximab trials have been completed in GAC. Phase 3 trials evaluating zolbetuximab in combination with front-line fluoropyrimidine plus platinum therapy improved survival endpoints compared to placebo plus chemotherapy in those with high CLDN18.2 positivity (>75% of tumor cells). This led to zolbetuximab's FDA approval in this population. Here, we review aspects of zolbetuximab's pharmacology known at this time.Expert opinion: Zolbetuximab is one of many agents targeting CLDN18.2 under development. Zolbetuximab in combination with chemotherapy has a slight impact on high CLDN18.2 expressed GAC to chemotherapy alone. Examining how to improve upon outcomes will be of benefit. Additionally, there are GAC subsets who may have benefit from zolbetuximab but need more close examination such as those with moderate CLDN18.2 expressed tumors, low CLDN18.2 expressed tumors, and CLD18-ARHGAP fusion patients.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"495-500"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143525569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk factors and prediction for DILI in clinical practice. 临床DILI的危险因素及预测。

Expert opinion on drug metabolism & toxicology Pub Date : 2025-05-01 Epub Date: 2025-02-23 DOI: 10.1080/17425255.2025.2468200

Helgi Kristinn Björnsson, Einar Stefan Björnsson

引用次数: 0

A comprehensive update on the human leukocyte antigen and idiosyncratic adverse drug reactions. 关于人类白细胞抗原和特殊药物不良反应的全面更新。

Expert opinion on drug metabolism & toxicology Pub Date : 2025-05-01 Epub Date: 2025-01-23 DOI: 10.1080/17425255.2025.2455388

Abdelbaset A Elzagallaai, Awatif M Abuzgaia, Michael J Rieder

{"title":"A comprehensive update on the human leukocyte antigen and idiosyncratic adverse drug reactions.","authors":"Abdelbaset A Elzagallaai, Awatif M Abuzgaia, Michael J Rieder","doi":"10.1080/17425255.2025.2455388","DOIUrl":"10.1080/17425255.2025.2455388","url":null,"abstract":"Introduction: Idiosyncratic adverse drug reactions (IADRs) or drug hypersensitivity reactions (DHRs) represent a major health problem because they are unpredictable and can be severe with potential life-long or even lethal consequences. Their pathophysiology is not clear but thought to be immune mediated, supported by the significant statistical association of these reactions with specific alleles of the human leukocyte antigen (HLA) gene.Area covered: This comprehensive update review summarizes the currently available evidence on the role of HLA gene locus in IADRs and discusses the present understanding of the pathophysiology of IADRs. We searched the available literature in PubMed and Google Scholar with no date restriction for publications on HLA and adverse drug reactions. Findings are summarized and discussed in the context of the currently available evidence.Expert opinion: The role of the immune system in IADRs and the role of pharmacogenetic testing in this field is evident. HLA genetic testing is very promising in the management of these reactions. Many obstacles seem to prevent pharmacogenetic testing to meet its full potential including cost and health care providers' education. Further work in needed to provide more evidence and allow widespread use of pharmacogenetic testing in the clinical practice.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"551-562"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143025884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sex-specific UGT expression and function: prevalence, potential mechanisms and significance. 性别特异性 UGT 表达和功能：普遍性、潜在机制和意义。

Expert opinion on drug metabolism & toxicology Pub Date : 2025-05-01 Epub Date: 2025-03-14 DOI: 10.1080/17425255.2025.2476794

Robyn Meech, Dong Gui Hu, Julie-Ann Hulin, Peter I Mackenzie

{"title":"Sex-specific UGT expression and function: prevalence, potential mechanisms and significance.","authors":"Robyn Meech, Dong Gui Hu, Julie-Ann Hulin, Peter I Mackenzie","doi":"10.1080/17425255.2025.2476794","DOIUrl":"10.1080/17425255.2025.2476794","url":null,"abstract":"Introduction: Sex and gender influence pharmacotherapy outcomes, including adverse drug effects which are nearly twice as common in women. Sex differences in drug responses involve factors as diverse as body composition, physiology, and prescribing patterns. Many drugs show higher exposure in women, which can be partly attributed to sex-differences in processes that control drug disposition such as metabolism and transport.Areas covered: This article reviews sex differences in the expression and function of the critical phase II drug-metabolizing enzymes, UDP-glucuronosyltransferases (UGTs). We curate the literature on sex-biased UGT expression in human tissues, describe the evidence for UGT-mediated sex-differences in drug exposure, and critically evaluate whether UGTs contribute to different drug outcomes in males and females. Relevant literature was identified by searching PubMed with terms including UDP-glucuronosyltransferase/UGT, glucuronidation/glucuronide, sex, gender, male, female, men, and women.Expert opinion: Several examples of sex-biased UGT expression and drug glucuronidation were identified; however, evidence of clinical impact was more limited. Significant data gaps limit our understanding of the prevalence and importance of sex-biased glucuronidation. Novel methodologies for tissue-level metabolite sampling together with increased sex-aware analysis of clinical/preclinical data, could help address gaps and reveal new avenues for enhancing pharmacotherapy outcomes for all genders.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"511-518"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143627242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacokinetic characteristics of risperidone ISM for the treatment of schizophrenia. 利培酮ISM治疗精神分裂症的药代动力学特征。

Expert opinion on drug metabolism & toxicology Pub Date : 2025-05-01 Epub Date: 2025-03-03 DOI: 10.1080/17425255.2025.2474126

Georgios Schoretsanitis, Christoph U Correll

{"title":"Pharmacokinetic characteristics of risperidone ISM for the treatment of schizophrenia.","authors":"Georgios Schoretsanitis, Christoph U Correll","doi":"10.1080/17425255.2025.2474126","DOIUrl":"10.1080/17425255.2025.2474126","url":null,"abstract":"Introduction: Risperidone-ISM is a novel intramuscular long-acting injectable formulation (LAI) of risperidone approved for the treatment of schizophrenia in adults. Knowledge regarding the pharmacokinetic properties of risperidone-ISM can improve care.Areas covered: We assessed the pharmacokinetic properties of risperidone-ISM. Most importantly, risperidone-ISM achieves therapeutic blood levels within 12-48 h after the first injection without the need for overlapping oral cotreatment, loading dose, or booster injection. Second, the in-situ microparticle (ISM) technology achieves stable blood levels, allowing currently 1-monthly injections. Third, females and patients with higher body mass index may have lower risperidone-ISM clearance, translating into higher risperidone serum levels. Fourth, there are only minimal risperidone-ISM clearance differences between deltoid and gluteal injections that balance out at steady state. However, aspects including pharmacogenetic and drug-drug interactions involving risperidone-ISM would benefit from further clarification.Expert opinion: Risperidone-ISM achieves therapeutic blood levels within 12-48 h after a single injection, currently lasting for 1 month, easing the initiation of a LAI risperidone formulation in adults with schizophrenia where LAIs remain underutilized. Prescriptions of LAIs, including risperidone-ISM, are likely to increase with an improved understanding of pharmacokinetic profiles and patient acceptability and outcomes, including in real-world settings informing drug selection.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"501-509"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143525571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating the synergistic use of advanced liver models and AI for the prediction of drug-induced liver injury. 评估先进肝脏模型与人工智能在药物性肝损伤预测中的协同作用。

Expert opinion on drug metabolism & toxicology Pub Date : 2025-05-01 Epub Date: 2025-02-02 DOI: 10.1080/17425255.2025.2461484

Yitian Zhou, Yi Zhong, Volker M Lauschke

{"title":"Evaluating the synergistic use of advanced liver models and AI for the prediction of drug-induced liver injury.","authors":"Yitian Zhou, Yi Zhong, Volker M Lauschke","doi":"10.1080/17425255.2025.2461484","DOIUrl":"10.1080/17425255.2025.2461484","url":null,"abstract":"Introduction: Drug-induced liver injury (DILI) is a leading cause of acute liver failure. Hepatotoxicity typically occurs only in a subset of individuals after prolonged exposure and constitutes a major risk factor for the termination of drug development projects.Areas covered: We provide an overview of available human liver models for DILI research and discuss how they have been used to aid in early risk assessments and to mitigate the risk of project closures due to DILI in clinical stages. We summarize the different data that can be provided by such models and illustrate how these diverse data types can be interfaced with machine learning strategies to improve predictions of liver safety liabilities.Expert opinion: Advanced human liver models closely mimic human liver phenotypes and functions for many weeks, allowing for the recapitulation of hepatotoxicity events in vitro. Integration of the biochemical, histological, and toxicogenomic output data from these models with physicochemical compound properties using different machine learning architectures holds promise to enhance preclinical DILI predictions. However, to realize this aim, it is important to benchmark the available liver models on test sets of DILI positive and negative compounds and to carefully annotate and share the resulting data.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"563-577"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143076769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preventable serious drug-disease interactions of reserve antibiotics. 储备抗生素可预防的严重药物-疾病相互作用。

Expert opinion on drug metabolism & toxicology Pub Date : 2025-05-01 Epub Date: 2025-03-05 DOI: 10.1080/17425255.2025.2473439

Slobodan M Janković, Snežana V Janković, Dobrivoje Stojadinović

{"title":"Preventable serious drug-disease interactions of reserve antibiotics.","authors":"Slobodan M Janković, Snežana V Janković, Dobrivoje Stojadinović","doi":"10.1080/17425255.2025.2473439","DOIUrl":"10.1080/17425255.2025.2473439","url":null,"abstract":"Introduction: Antibiotics that are used exclusively in hospital settings and reserved for treating infections caused by multidrug-resistant or extended-resistant bacterial pathogens are referred to as 'reserved' antibiotics. The purpose of this review article is to provide a better understanding of the risks associated with serious interactions between reserved antibiotics and various diseases, as well as to present key strategies for their prevention.Areas covered: The literature search was conducted in the MEDLINE, SCOPUS, EBSCO, and GOOGLE SCHOLAR databases without any restrictions on time or language. Only clinical studies, observational human studies, case reports, and case series that reported serious drug-disease interactions were considered.Expert opinion: Knowledge of the interactions between reserve antibiotics and diseases, that have actually occurred and then been described in the medical literature, is crucial to the safe treatment of critically ill patients with infections caused by multidrug-resistant bacterial strains. Introducing into routine practice the checking of possible interactions with diseases that a patient suffers from, strict monitoring of changes in the function of the excretory organs (kidneys and liver), and measuring the concentration of drugs in the plasma will reduce the possibility of adverse drug-disease interactions.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"535-550"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143532267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0